Our Pricing

Buy Wegovy UK: Private Prescription Without GP Referral

Published on: June 03, 2026

When you buy Wegovy UK private prescription through Cured Pharmacy, you access UK-licensed semaglutide injections from £79.00 without needing a GP referral. Our UK-registered prescribers complete your clinical assessment in under 3 minutes, and genuine medication ships discreetly to your door within days.

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with weight-related comorbidities [1]. Semaglutide mimics the natural GLP-1 hormone your gut produces after eating, slowing gastric emptying and signalling satiety to your brain.

In the landmark STEP 1 trial involving 1,961 adults, participants using Wegovy achieved an average 14.9% body weight reduction over 68 weeks compared to 2.4% with placebo [1]. Approximately two-thirds of participants lost at least 10% of their baseline weight, and nearly half lost 15% or more. These results represent some of the most significant weight loss outcomes observed in pharmacological trials to date.

The once-weekly subcutaneous injection delivers consistent semaglutide levels throughout the week, eliminating the need for daily dosing. Your prescriber will typically start you on a 0.25 mg dose and gradually increase over 16-20 weeks to the maintenance dose of 2.4 mg, minimising gastrointestinal side effects during the titration period [2].

Buy Wegovy UK Private Prescription: The Online Process

Purchasing Wegovy through a UK-registered online pharmacy eliminates the traditional barriers many patients face. At Cured Pharmacy, the entire process from consultation to delivery typically completes within 3-5 working days, and you'll see transparent pricing before starting your assessment.

Our clinical team, overseen by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), reviews every consultation personally. The online assessment covers your medical history, current medications, weight loss goals, and any contraindications to semaglutide therapy. Unlike some services that require GP letters or referrals, our UK prescribers can issue private prescriptions directly based on clinical suitability.

What Happens After Your Assessment

Once approved, your prescription is dispensed from our GPhC-registered pharmacy (9012511) and shipped in 100% discreet packaging with no external branding. Each Wegovy pen arrives with complete dosing instructions, injection technique guidance, and access to our clinical support team throughout your treatment journey.

Wegovy Price UK: What You Actually Pay

Wegovy pricing varies significantly across UK providers, but at Cured Pharmacy you'll find competitive rates with complete transparency. Our pricing starts from £79.00 per pen, with the exact cost depending on your prescribed dose and treatment duration.

Many patients appreciate seeing the full price before completing their consultation — there are no hidden fees, no subscription lock-ins, and no surprise charges at checkout. The price you see includes the medication, UK prescriber consultation, pharmacy dispensing, and discreet home delivery.

For ongoing treatment, most patients continue with the 2.4 mg maintenance dose once weekly. Purchasing multiple pens in advance can reduce per-pen costs, and our clinical team can discuss treatment duration during your assessment based on your individual weight loss goals and response to therapy.

Private vs NHS Wegovy Access

NHS England currently restricts Wegovy prescribing to specialist weight management services in certain areas, with strict eligibility criteria and significant waiting lists. Private prescriptions offer immediate access for clinically suitable patients without the delays associated with NHS pathways, though costs are not covered by the NHS.

Wegovy vs Saxenda: Comparing Semaglutide and Liraglutide

Both Wegovy and Saxenda are GLP-1 receptor agonists licensed for weight management in the UK, but they differ in molecular structure, dosing frequency, and clinical outcomes. Saxenda contains liraglutide and requires daily subcutaneous injections, whilst Wegovy uses the longer-acting semaglutide administered once weekly [3].

Head-to-head trial data shows semaglutide produces greater weight loss than liraglutide. In the STEP 8 trial, participants on semaglutide 2.4 mg lost an average of 15.8% body weight compared to 6.4% with liraglutide 3.0 mg over 68 weeks [3]. The once-weekly dosing schedule of Wegovy also improves treatment adherence for many patients who find daily injections burdensome.

Your UK prescriber will consider factors including your injection preference, previous GLP-1 experience, and individual response when recommending the most suitable treatment. Some patients prefer starting with daily injections for more granular dose control, whilst others prioritise the convenience of weekly administration.

Common Side Effects and How to Manage Them

Gastrointestinal side effects are the most frequently reported adverse events with Wegovy, particularly during dose escalation. In clinical trials, nausea affected approximately 44% of participants, diarrhoea 30%, vomiting 24%, and constipation 24% [1]. These symptoms typically peak during the first few weeks after dose increases and diminish as your body adapts to higher semaglutide levels.

Practical management strategies can significantly reduce symptom severity. Eating smaller, more frequent meals rather than large portions helps minimise nausea. Avoiding high-fat, greasy, or heavily spiced foods during the first weeks of treatment reduces gastrointestinal upset. Staying well-hydrated and increasing dietary fibre intake helps manage constipation, whilst anti-emetics prescribed by your GP can address persistent nausea if needed.

Serious adverse events are rare but require immediate medical attention. These include signs of pancreatitis (severe abdominal pain radiating to the back), gallbladder problems (right upper abdominal pain, fever, jaundice), or allergic reactions (rash, difficulty breathing, facial swelling). Contact your prescriber or seek emergency care if you experience any of these symptoms [2].

When Wegovy May Not Be Suitable

Wegovy is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It should not be used during pregnancy or breastfeeding, and women of childbearing potential should use effective contraception during treatment. Your UK prescriber will review your complete medical history to ensure semaglutide is clinically appropriate for you.

Maximising Weight Loss Results with Wegovy

Whilst Wegovy produces significant weight loss as monotherapy, combining medication with lifestyle modifications optimises outcomes. Clinical trial participants received counselling on reduced-calorie diets (approximately 500 kcal daily deficit) and increased physical activity (150 minutes weekly moderate exercise) alongside semaglutide injections [1].

The medication works synergistically with behavioural changes by reducing hunger and food cravings, making dietary adherence easier. Many patients report feeling satisfied with smaller portions and experiencing fewer urges to snack between meals. This pharmacological support can help overcome the physiological adaptations that typically sabotage weight loss efforts.

Long-term success requires ongoing treatment in most cases. The STEP 4 trial demonstrated that participants who discontinued Wegovy after 20 weeks regained approximately two-thirds of their lost weight over the following year, whilst those continuing treatment maintained their weight loss [4]. Your prescriber will discuss appropriate treatment duration based on your individual goals, response, and any emerging safety concerns.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Novo Nordisk. (2023). Wegovy 2.4 mg Solution for Injection in Pre-filled Pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
3. Rubino, D. M., et al. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA, 327(2), 138–150. https://doi.org/10.1001/jama.2021.23619 [accessed 13 August 2026]
4. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is indicated for weight management in adults with BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities, alongside reduced-calorie diet and increased physical activity.